TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
TScan Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $7.11M, up 2.2% year over year. For fiscal 2025 it was $10.33M, up 266.7% from the year before. The highest annual figure on record is $21.05M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.33M | +266.7% |
| FY2024 | Dec 31, 2024 | $2.82M | -86.6% |
| FY2023 | Dec 31, 2023 | $21.05M | +55.5% |
| FY2022 | Dec 31, 2022 | $13.54M | +33.5% |
| FY2021 | Dec 31, 2021 | $10.14M | +834.7% |
| FY2020 | Dec 31, 2020 | $1.09M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.05M | -65.8% |
| Q1 FY2026 | Mar 31, 2026 | $982.00K | -54.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.57M | +286.0% |
| Q3 FY2025 | Sep 30, 2025 | $2.51M | +139.4% |
| Q2 FY2025 | Jun 30, 2025 | $3.08M | +473.9% |
| Q1 FY2025 | Mar 31, 2025 | $2.17M | +283.6% |
| Q4 FY2024 | Dec 31, 2024 | $665.00K | -90.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.05M | -73.0% |
| Q2 FY2024 | Jun 30, 2024 | $536.00K | -83.0% |
| Q1 FY2024 | Mar 31, 2024 | $566.00K | -91.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.21M | +133.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.89M | +15.6% |
| Q2 FY2023 | Jun 30, 2023 | $3.15M | -22.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.80M | +125.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.10M | +8.4% |
| Q3 FY2022 | Sep 30, 2022 | $3.36M | +39.4% |
| Q2 FY2022 | Jun 30, 2022 | $4.06M | +42.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.02M | +49.0% |
| Q4 FY2021 | Dec 31, 2021 | $2.85M | +259.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.41M | +731.7% |
| Q2 FY2021 | Jun 30, 2021 | $2.85M | – |
| Q1 FY2021 | Mar 31, 2021 | $2.03M | – |
| Q4 FY2020 | Dec 31, 2020 | $795.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $290.00K | – |
See a number that looks wrong?